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Abstract
Small cell lung cancer (SCLC) is an aggressive disease in which, after initial sensitivity to platinum/etoposide che-
motherapy, patients frequently relapse with drug-resistant disease. Deregulation of the Bcl-2 pathway is implicated
in the pathogenesis of SCLC, and early phase studies of Bcl-2 inhibitors have been initiated in SCLC. Obatoclax is a
small-molecule drug designed to target the antiapoptotic Bcl-2 family members to a proapoptotic effect. Preclinical
studies were conducted to clarify the kinetics of obatoclax-induced apoptosis in a panel of SCLC cell lines to assist
with the interpretation of biomarker data generated during early phase clinical trials. In vitro, obatoclax was syn-
ergistic with cisplatin and etoposide, and “priming” cells with obatoclax before the cytotoxics maximized tumor
cell death. Peak levels of apoptosis, reflected by cleaved cytokeratin 18 (CK18) levels (M30 ELISA) and caspase
activity (SR-DEVD-FMK), occurred 24 hours after obatoclax treatment. A phase 1b-2 trial of obatoclax administered
using two infusion regimens in combination with carboplatin and etoposide has been completed in previously
untreated patients with extensive-stage SCLC. Circulating pharmacodynamic biomarkers of cell death, full-length
and/or cleaved CK18, and oligonucleosomal DNA were studied in the phase 1b trial. All SCLC patients classified as
“responders” after two cycles of treatment showed significantly increased levels of full-length and cleaved CK18
(M65 ELISA) on day 3 of study. However, the preclinical data and the absence of a peak in circulating caspase-
cleaved CK18 in trial patients suggest suboptimal timing of blood sampling, which will need refinement in future
trials incorporating obatoclax.
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Introduction
The suppression of apoptosis is recognized as a hallmark of human
cancer [1] and is an established mechanism for pleiotropic drug re-
sistance. Consequently, global drug discovery efforts have been mar-
shalled to target those molecules that increase the cellular threshold
for apoptosis in tumor cells and resensitize drug-resistant tumors.
Small cell lung cancer (SCLC) is initially a chemosensitive tumor re-
sponding well to etoposide and platinum-based doublet therapy [2].
However, tumor relapse with drug-resistant disease is common, and
novel therapies to combat this aggressive cancer are urgently re-
quired. Interactions between antiapoptotic and proapoptotic proteins
of the Bcl-2 family determine the threshold for apoptosis (reviewed
by Letai [3]). The antiapoptotic family members (Bcl-2, Bcl-xL, Bcl-w,
Mcl-1, and A1) are overexpressed in many human tumor types pre-
sumably to combat the cellular stress of the tumor microenviron-
ment and inherent cellular damage [4]. Bcl-2 itself is upregulated in
at least 75% of SCLC [5–8], and drugs targeting Bcl-2 in SCLC pa-
tients have entered early clinical trials [9,10].
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Obatoclax (Gemin X Pharmaceuticals) is a novel proapoptotic
drug designed to target the BH-3 domain of prosurvival Bcl-2 family
members and has been shown to increase expression of BH-3–only
proteins Bim and Noxa [11,12]. Obatoclax demonstrated promising
preclinical efficacy against non–small cell lung carcinoma (NSCLC),
mantle cell lymphoma, and multiple myeloma cells both as a single
agent and in combination with clinically relevant cytotoxics in vitro
[13–15]. Moreover, in combination with the proteosome inhibitor
bortezomib, obatoclax was synergistic in both mantle cell lymphoma
and multiple myeloma. This is of particular interest as Mcl-1 is turned
over at a steady state due to proteasomal degradation [16], potentially
resulting in the accumulation of Mcl-1 and resistance to apoptosis.
In multiple myeloma, the sequence of obatoclax and bortezomib treat-
ment was critical, with synergy maximized by obatoclax pretreatment
[15]. Obatoclax has also demonstrated enhanced apoptosis in combi-
nation with Apo2L/TRAIL in cholangiocarcinoma cells [17] and pan-
creatic cancer cells [18] and with tyrosine kinase inhibitors in breast
cancer [19] and NSCLC [14]. These data provided the stimulus for
the clinical development of obatoclax and further preclinical studies
in SCLC to optimize the utility of pharmacodynamic biomarkers of
cell death.
Obatoclax has displayed single agent antitumor activity in phase 1
trials using a variety of infusion schedules (1, 3, and 24 hours) in
patients with advanced hematological malignancies [20,21]. To assess
the quantitative effect of obatoclax on apoptosis induction, serial
measurements of oligonucleosomal DNA/histone complexes (nDNA;
Cell Death Detection ELISAPLUS Roche, Basel, Switzerland) were
analyzed. Circulating nDNA concentrations were directly propor-
tional to obatoclax dose, and after an initial increase in response to
treatment, elevated nDNA was sustained for several days. In a phase 1
trial of obatoclax plus topotecan in relapsed SCLC and other solid
tumors, two patients with SCLC achieved partial responses and four
patients stable disease [22]. A phase 1b trial of obatoclax in combi-
nation with carboplatin and etoposide, in previously untreated pa-
tients with extensive-stage small cell lung cancer (ES-SCLC), has
recently concluded. Here, the primary objective was to determine
the maximum tolerated doses of obatoclax given in a 21-day cycle
(in separate dose escalations as either a 3- or a 24-hour infusion
on days 1-3) [23]. High early tumor response rates were observed,
and dose-limiting toxicities of somnolence, euphoria, and disorienta-
tion were reported in the 3-hour regimen. Dose-limiting toxicities
were not observed in the 24-hour infusion regimen, and response
rates with this regimen seemed to be lower. Three pharmacodynamic
end points of cell death measured in serial peripheral blood sam-
ples were incorporated into the trial: the M30 Apoptosome ELISA
(M30) that detects caspase-cleaved forms of cytokeratin 18, the M65
ELISA (M65) that detects full-length and caspase-cleaved cytokeratin
18, and the nDNA assay. We have previously reported the utility of
these blood-borne biomarkers in SCLC patients treated with con-
ventional etoposide and platinum-based therapy [24] where their
levels increased after cytotoxic drug treatment and returned to base-
line levels during the following 21 days, mirroring initial tumor re-
sponse. These data have served as a guide to the interpretation of the
biomarker results presented in the phase 1b trial. In parallel, pre-
clinical studies were performed in a panel of SCLC cell lines to eval-
uate the kinetics of biomarker change in obatoclax-induced apoptosis
when the drug is administered as a single agent or in combination
with etoposide and cisplatin and to assess the impact of a variety
of drug schedules.
The preclinical analysis demonstrated that obatoclax was syner-
gistic with cisplatin and etoposide across a panel of SCLC cell lines
with maximum apoptosis occurring 24 hours after pulsed obatoclax
treatment. Priming cells with obatoclax before the cytotoxics maxi-
mized tumor cell death. The clinical pharmacodynamic biomarker
data showed that SCLC patients categorized as “responders” had
significant increases in circulating cytokeratin 18 (CK18) during
obatoclax exposure indicative of both apoptotic and nonapoptotic
cell death. In view of the preclinical data, the absence of a discernable
peak in caspase-cleaved CK18 after drug treatment in patients in
this phase 1b trial may suggest suboptimal timing of patient blood
sampling, which will need to be considered and rectified in future
trial designs.
Materials and Methods
Human SCLC Cell Lines, Reagents, and Chemicals
Human SCLC cell lines (H82, DSM114, H146, H196, H345,
H524, and H526) were obtained from the American Type Culture
Collection (Manassas, VA). Cell lines were authenticated using the
Applied Biosystems AmpFlSTR system. All cell lines were main-
tained in RPMI 1640 supplemented with 10% fetal bovine serum.
Obatoclax was provided by Gemin X Inc (Malvern, PA) and dis-
solved in 100% dimethyl sulfoxide for in vitro assays. All cytotoxics
were purchased from Sigma-Aldrich (Gillingham, UK).
Cell Proliferation Assay
The MTS assay (CellTiter 96 AQueous Non-Radioactive Cell
Proliferation Assay; Promega, Madison, WI) [25] was used to de-
termine cell population growth. SCLC cell lines were plated in ex-
ponential growth phase in 96-well plates and treated with varying
concentrations of obatoclax. At various times thereafter, cells were
stained according to the MTS protocol, and absorbance was mea-
sured using a microplate reader (Labsystems Multiskan EX; Thermo
Scientific, Milford, MA) at 490 nm.
FACS Array
SCLC cells were treated with obatoclax using the half-maximal in-
hibitory concentrations (IC50) derived from the MTS assay. Cells were
harvested and resuspended in 1 ml of RPMI with 10% FBS; 100 μl of
each test sample was added to a 96-well U-bottom plate (Falcon 3077;
Becton Dickinson, Franklin Lakes, NJ). SR-DEVD-FMK (10 μl,
CaspaTag 3,7; Millipore, Billerica, MA) was incubated for 1 hour at
37°C in the dark before analysis by flow cytometry (BD FACSArray
Bioanalyzer). CaspaTag fluorescence was detected at 595 nm after
fluorochrome excitation at 532 nm. Electronic gating of live or dead
subpopulations was defined by gating using control samples of un-
treated cells and etoposide (20 μM) cells. A total of 20,000 cells were
analyzed per sample.
Immunoblot Assay
Cells were treated with obatoclax or vehicle control for the stated
times. Protein lysates were prepared using lysis buffer (Cell Signaling
Technology, Danvers, MA) and protease inhibitor cocktail (Sigma-
Aldrich). All samples were sonicated at 10 Hz for 10 seconds. Protein
lysates were resolved by electrophoresis in appropriate percentage poly-
acrylamide gels and transferred to polyvinylidene fluoride (PVDF)
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membranes (Immobilon, Millipore, Watford, UK). Standard immu-
noblot analysis procedures were followed with overnight incubation
at 4°C with the following primary antibodies: A1 1:1000 (Abcam,
Cambridge, UK), Bcl-2 1:1000 (Dako UK Ltd, Ely, UK), Bcl-w
1:1000 (Alexis Biochemical, Lausen, Switzerland), Bcl-xL 1:1000
(BD Transduction Laboratories, Oxford, UK), Mcl-1 1:1000 (BD Bio-
sciences, Oxford, UK), cleaved caspase-3 1:500 (Cell Signaling Tech-
nology), cleaved poly (ADP-ribose) polymerase (PARP; Cell Signaling
Technology), and tubulin (Cancer Research UK, London). Blots were
visualized with the enhanced chemiluminescence system (Amersham,
Chalfont St. Giles, UK) and analyzed using a Fuji LAS-1000 Plus imag-
ing system with AIDA software (Fuji, Bedford, UK). The proportion
of cleaved caspase-3 was measured using the Meso Scale Discovery
MULTISPOT Cleaved/Total Caspase-3 Assay (Meso Scale Discovery,
Gaithersburg, MD) according to the manufacturer’s instructions.
Drug Combination Assays
The combination index (CI) method was applied based on the
multiple drug effect equation of Chou and Talaly [26]. Obatoclax
was tested in combination with both cisplatin and etoposide (used
in the treatment of SCLC patients), considering cisplatin and etopo-
side as a single entity and obatoclax as the second agent. The IC50 of
cisplatin and etoposide combined was determined using the MTS
assay before combination studies to account for synergy between
the chemotherapeutics. Cells were either treated for 96 hours with
obatoclax, cisplatin + etoposide, or with obatoclax and cisplatin +
etoposide in 48-hour sequencing experiments. Eight drug concentra-
tions were used covering the concentration effect. Drug additivity is
reported in the range CI = 0.9 to 1.1, synergy CI < 0.9, and antag-
onism CI > 1.1.
Clinical Trial Pharmacodynamic Analysis
The phase 1b trial of obatoclax was a dose-escalation study of
obatoclax administered every 3 weeks in combination with carboplatin
and etoposide to patients with previously untreated ES-SCLC [23]. The
study was sponsored by Gemin X Pharmaceuticals (NCT00682981).
The primary objective was to determine the recommended phase 2
dose of obatoclax administered either as a 3- or 24-hour infusion
for three consecutive days in combination with carboplatin (AUC5,
day 1) and etoposide (100 mg/m2, days 1-3) in a three-weekly cycle
for six cycles (Figure 4A). This was followed by prophylactic cranial
irradiation (for complete responders and partial responders) and with
three-weekly maintenance of obatoclax. The M30, M65, and nDNA
ELISAs were performed according to the manufacturer’s instructions
and to GCP standards (Standard Operating Procedures: LM/003,
LM/004, and LM/016) and were read using a Dynex MRXII Plate
Reader (Dynex Technologies, Chantilly, VA). Patient serum samples
were drawn for analysis on days 1, 3, and 8 of cycle 1. Samples were
analyzed in duplicate. The dynamic ranges of these ELISAs are 0 to
1000 U/L (M30), 0 to 2000 U/L (M65), and 0.1 to 3.5 o.d. (nDNA).
Statistics
Statistical significance (P ≤ .05) for a change in M30 concentration
was determined by two-tailed paired t tests (assuming equal variance)
between the drug combination counts and the single agents. For the
biomarker data, the Mann-Whitney test was used to compare differ-
ences between the two unmatched infusion protocols. Intrapatient
comparisons were analyzed using Wilcoxon matched-pairs signed rank
test to compare medians.
Results
Obatoclax Reduced Cell Viability across the SCLC Cell
Line Panel
Obatoclax caused concentration-dependent reduction in viable cells
in all tested SCLC cell lines, as measured by the MTS assay at 96 hours
(Figure 1, A and B). The range of IC50 concentrations was 0.08 to
1.04 μM, and in most instances, the IC50 was less than 0.2 μM.
The order of increasing resistance (judged by IC50 concentration) after
a 96-hour constant drug challenge was as follows: H526 > H146 >
DMS 114 > H82 > H345 > H524 > H196. Cell lines were also treated
for 24, 48, and 72 hours with obatoclax concentrations ranging from
0.01 to 5 μM. Maximal effect on cell viability was observed after
96 hours of obatoclax exposure, with near-maximal effect at 72 hours
of exposure. In most cell lines, IC50 values after 24 and 48 hours of
treatment were several fold higher, with only two SCLC cell lines
(H526 and DMS114) sensitive to a 48-hour obatoclax treatment, sug-
gesting that a prolonged exposure was generally required for cyto-
toxicity in vitro.
Obatoclax Induced Time- and Concentration-Dependent
Apoptosis in SCLC Cell Lines
Analysis of cleaved PARP and cleaved caspase-3 levels in obatoclax-
treated SCLC cell lines confirmed time- and concentration-dependent
effects on cell death (Figure 2, A and B (representative data for H526
shown)), suggesting that the observed reduction in viable cells oc-
curred by apoptosis. To provide further confirmatory evidence of
apoptotic cell fate, H526 cells treated for 48 hours with obatoclax were
analyzed using SR-DEVD-FMK (to report caspase-3 and -7 activity)
and caspase-cleaved CK18 (M30) immediately after pulsed treatment,
as well as 1 day and 2 days after the drug had been removed and re-
placed with drug-free medium (Figure 2C). Caspase-3/7 activity was
highest 24 hours after obatoclax removal, consistent with significantly
high M30 values at this time point (Figure 2C ; P < .01), which accu-
mulated in the supernatant after drug removal.
Protein Expression Levels of Antiapoptotic Bcl Family
Members in SCLC
The expression levels of antiapoptotic Bcl-2 family members varied
across the SCLC panel (Figure 1C ) and were consistent with pre-
viously reported data [27,28]. The relative affinity of obatoclax for
Bcl-2 is believed to be fourfold higher than for Bcl-xL [12], leading
to the hypothesis that obatoclax sensitivity would correlate better with
high Bcl-2 expression than with high Bcl-xL expression. Up-regulation
of both of these proteins has been shown to have prognostic signifi-
cance in a variety of tumor types in immunohistochemical studies
[29,30], but none of these studies have examined the relative abun-
dance of all antiapoptotic Bcl-2 familymembers.However, overall, there
is no clear relationship between Bcl-2 family protein expression and
sensitivity to obatoclax across the SCLC cell line panel.
Obatoclax, Cisplatin, and Etoposide Are a Synergistic
Drug Regimen
The observations that conventional cytotoxics induce apoptosis
through the intrinsic pathway and that apoptosis is suppressed by
upregulated levels of antiapoptotic Bcl-2 family proteins led to the pre-
diction that Bcl-2 inhibition should increase antitumor efficacy of
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standard cytotoxic chemotherapy [31,32]. SCLC is considered to be a
chemosensitive tumor and combination chemotherapy with platinum
and etoposide is the standard regimen for ES-SCLC with four to
six cycles considered optimal [2]. Therefore, the effects of obatoclax
in combination with cisplatin and etoposide were explored using the
CI method. Table 1 shows that obatoclax plus cisplatin and etopo-
side was a synergistic drug regimen with CI values less than 0.9
(shaded cells). Synergy was also observed in the combination effect
graph (Figure 3A). The surviving fraction was less for the combina-
tion compared with either chemotherapy or obatoclax alone, demon-
strated by a left shift in the curve. Priming the cells with obatoclax
for 48 hours resulted in the greatest synergy, enhancing the effect of
cisplatin and etoposide (Figure 3B). This was observed in all SCLC
cell lines tested, consistent with the hypothesis that obatoclax re-
duces the cellular threshold for cytotoxic induced apoptosis. In only
one of the cell lines, H526, both sequences of treatment were syn-
ergistic, implying that, for this cell line, synergy occurred indepen-
dently of sequencing.
Evaluation of Circulating Biomarkers of Cell Death in the
Phase 1 Trial of Obatoclax
The phase 1b trial of obatoclax was a dose-escalation study of
obatoclax administered every 3 weeks to patients with ES-SCLC in
combination with carboplatin and etoposide [23] (Figure 4A). Pa-
tient serum samples were drawn for analysis on days 1, 3, and 8 of
cycle 1, and in total, 24 sets of samples were received. Seventeen pa-
tients were classified as “responders” and seven patients were classi-
fied as “nonresponders” according to RECIST criteria [33] at an early
time point after cycle 2 of treatment and compared with baseline
scans. Responders were considered to have radiologic unconfirmed
complete or partial responses after two cycles of treatment, whereas
nonresponders were patients with stable disease or disease progression.
Responders, but not nonresponders, demonstrated significant increases
in circulating full-length and/or cleaved CK18 values (M65) only be-
tween days 1 and 3 (P = .037) and a trend toward decreased M65
values at day 8 (that did not reach significance, P = .08; Figure 4B).
The biomarker profiles for each infusion regimen were compared
to identify which regimen was associated with the largest change in
cell death biomarker concentration. In all patients, there was a signif-
icant percentage change from baseline between day 3 biomarker in-
creases and day 8 decreases in M65 and nDNA (P = .002 and P =
.02, respectively; Figure 4C ). Group comparisons between patients
who received the 3-hour infusion (n = 16) and those who received
the 24-hour infusion (n = 8) showed that the 24-hour infusion reg-
imen had significantly higher day 3 nDNA values (P = .01) compared
with the 3-hour infusion regimen, a trend that was also observed
in the M65 results (P = .08; Figure 4C ). No significant differences
Figure 1. Obatoclax decreased the viability of SCLC cells with no clear correlation with antiapoptotic Bcl-2 family protein expression
levels. (A) Concentration-effect curves for a panel of SCLC cell lines treated at varying concentrations of obatoclax for 96 hours, using
the MTS assay. (B) IC50 values for log phase SCLC cells, treated with obatoclax for 96 and 72 hours. (C) Immunoblot analysis of anti-
apoptotic Bcl-2 family members in SCLC cell lines. Untreated log-phase SCLC cells were lysed, and lysates were normalized for total
protein content (15 μg per lane) and analyzed by SDS-PAGE using antibodies recognizing A1, Bcl-2, Bcl-w, Bcl-xL, and Mcl-1. Tubulin was
used as a protein loading control. Data are representative of n = 3 repeat experiments ± SEM.
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between the 3 and 24-hour infusion regimens were observed at day 8
or in the cleaved CK18 (M30) results. Within the 24-hour infusion
group, longitudinal data for individual patients (intrapatient compar-
isons) showed significant increases in both M65 and nDNA at day 3
(P = .01 and P = .004, respectively; data not shown).
Discussion
After the discovery that antiapoptotic Bcl-2 family proteins can sup-
press drug-induced apoptosis [34,35], one approach to restore a func-
tioning cell death program in drug-resistant cancer cells is to combine
Bcl-2–targeted drugs with standard of care chemotherapy. However,
attempts to target Bcl-2 in SCLC using Bcl-2 antisense oligonucleo-
tides, such as oblimersen in combination with carboplatin and etopo-
side in chemotherapy-naive patients, failed to show improvements in
response rates or survival [10]. Possible explanations for the failure of
this antisense approach are that oblimersen did not sufficiently sup-
press intratumoral levels of Bcl-2 or that functional redundancy exists
between Bcl-2 and other antiapoptotic family members such as Bcl-xL
and Mcl-1. The development of novel compounds with selective ac-
tivity for Bcl-2 and Bcl-xL has revealed the ability of cancer cells to
adapt [36] and express Mcl-1 as a resistance mechanism [37]. This
led to the proposition that small-molecule drugs that target the Bcl-2
family members less selectively may meet with greater therapeutic suc-
cess [38].
Here, the effect of combining obatoclax with platinum and etopo-
side chemotherapy in SCLC cell lines was evaluated, in parallel with
the same strategy in patients receiving treatment in the context of a
phase 1b trial. The rationale for this approach was to optimize drug
scheduling and the timing of pharmacodynamic sampling to inform
future trial design and test the validity of the combination treatment
as a therapeutic strategy. The preclinical studies demonstrated that
obatoclax induced apoptosis in a time- and concentration-dependent
manner across multiple SCLC cell lines and that it is synergistic with
clinically relevant chemotherapeutics. Similar to studies in NSCLC, no
obvious relationship between Bcl-2 family protein expression profiles
and sensitivity to obatoclax was observed [14]. Our preclinical results
Table 1. Priming Cells with Obatoclax Enhances the Effect of Cisplatin and Etoposide for All
Tested Cell Lines.
Cell Line Sequence
(A) Concurrent (B) Cytotoxics → Obatoclax (C) Obatoclax → Cytotoxics
H82 1.42 (−) 1.07 (±) 0.82 (++)
DMS114 1.35 (−) 1.22 (−) 0.69 (+++)
H146 1.24 (−) 0.92 (±) 0.79 (++)
H196 1.27 (−) 1.25 (−) 0.4 (+++)
H524 1.05 (±) 1.31 (−) 0.79 (++)
H526 1.23 (−) 0.80 (++) 0.78 (++)
Cells were treated with schedule A, B, or C for 96 or 48 hours in sequence using fixed ratios of the
IC50 values. Cisplatin and etoposide were considered a single entity, and obatoclax was considered
as the second agent. Cell viability was determined using the MTS assay, and synergy was evaluated
using CalcuSyn (BioSoft, Cambridge, England) where additivity is CI = 0.9 to 1.1 (±), antagonism
>1.1 (−), and synergy <0.9 (+). Results represent n = 3 independent experiments.
Shaded values represent synergistic combinations.
Figure 2. Obatoclax induced apoptosis in SCLC cells. (A and B) Immunoblot analysis of H526 cells treated with 48 hours of obatoclax at
the indicated concentrations (A) or with a fixed dose of 0.2 μM for the indicated times (B). Membranes were probed with antibodies
specific for cleaved (“c” as indicated) and full-length PARP. Cleaved caspase-3 as a percentage of total caspase-3 measured using the
Mesoscale Discovery assay are reported below. (C) Ratio of drug-treated and vehicle-treated H526 cells with respect to staining for
active caspase-3/7 by SR-DEVD-FMK by flow cytometry after cells were treated with obatoclax at the IC50 concentration for 48 hours,
then 1 day and 2 days after the drug was removed and replaced by medium. Levels of cleaved CK18 (by M30 assay) in the cell culture
medium after 48 hours of obatoclax at the IC50 concentration at the same time points. CTRL indicates control; ETOP, etoposide 20 μM.
Results are representative of n = 3 ± SEM.
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suggest that the optimal drug schedule is to “prime” cells with obato-
clax before chemotherapy, an observation consistent with sequencing
experiments with obatoclax and bortezomib in multiple myeloma
[15], and that peak apoptosis end points occur 24 hours after obato-
clax treatment.
The precise mechanism of action of several novel drugs designed
to interrupt the BH-3–mediated interactions between antiapoptotic
and proapoptotic Bcl-2 family is often tested by comparing their abil-
ity to induce apoptosis in Bak/Bax–deficient cells, the premise being
that pure BH-3 mimetics will be innocuous in this cellular context.
A comparison of six putative BH-3 mimetics (but not obatoclax)
showed that, in both short-term and clonogenic survival assays, cells
deficient in both Bax/Bak were killed at the same efficiency as wild-
type cells, strongly implying that none of these compounds function
as a pure BH-3 mimetic [37]. The mechanism of obatoclax-induced
apoptosis was initially reported to be Bax and/or Bak dependent, based
on studies using mouse kidney epithelial cells lacking Bax and Bak
that showed resistance to obatoclax induced DNA fragmentation
and caspase-3 cleavage [11]. However, using mouse embryonic fibro-
blasts, obatoclax-mediated cell killing was shown to be at least in part
dependent on Bax/Bak; mouse embryonic fibroblasts deficient in Bax/
Bak exhibited partial resistance and decreased colony-forming ability
[17]. These data suggest the existence of mechanisms of obatoclax-
induced cell death alternative to the established BH-3 sensitizer or
effector models that modulate Bcl-2 family interactions to drive apop-
tosis [39–41].
The phase 1b pharmacodynamic biomarker data showed a clear
and significant biomarker increase by day 3 in M65 and nDNA lev-
els followed by a decrease below pretreatment levels by day 8, con-
sistent with a biomarker profile indicative of treatment response in
SCLC patients and reflecting decreased tumor load due to treatment-
induced tumor cell death [42]. The lack of significant drug-induced
M30 effects, which measures apoptosis specifically, may have been
confounded by the combination with chemotherapeutics and cell loss
occurring by more than one mechanism. Chemonaive SCLC patients
typically respond well to carboplatin and etoposide in the first cycle,
making it difficult to dissect out the biomarker effects of obatoclax
alone. Comparing the 24- and 3-hour infusion regimens, the greatest
increase in biomarker levels on day 3 was observed for patients receiving
the 24-hour infusion regimen. However, the day 8 biomarker data
showed decreases below the pretreatment baseline only in the 3-hour
infusion regimen, which is typical of a biomarker profile in a patient
with SCLC responding to treatment [24,43]. In support of the 3-hour
regimen demonstrating superior efficacy, overall (after six cycles of
chemotherapy), the clinical data demonstrated a higher number of re-
sponders in the 3-hour schedule (12 vs 5). The reason the day 3 bio-
marker levels were noninformative in the 3-hour infusion arm may be
that the biomarker peak occurred earlier and that the timing of blood
sampling for was suboptimal. In the phase 1 trial of obatoclax in CLL
[21], activated Bax/Bak complexes in peripheral mononuclear cells,
detected by immunoprecipitation, peaked 1 to 3 hours after drug in-
fusion in a dose-dependent manner. Furthermore, our analyses of sero-
logical cell death biomarkers in chemonaive SCLC patients undergoing
platinum and etoposide chemotherapy indicated that the optimal
sampling time for the cell death assays was just 24 to 48 hours after
chemotherapy [24]. Detection of circulating cell death biomarkers is
dependent on many factors including tissue/tumor perfusion, tumor
turnover rate, susceptibility/“priming” of the cancer cell, and efficiency
of elimination processes [44]. Although decisions on the timing of sam-
pling for a new agent may be determined by preclinical data a priori,
it would be prudent to perform pilot studies during early clinical trials
of novel agents to optimize the timing of pharmacodynamic sampling.
We have analyzed circulating cell death biomarkers in mice bearing hu-
man SCLC xenografts treated with a proapoptotic dose of the BH-3
mimetic ABT-737 [45] and showed significant increases in circulating
cleaved CK18 as early as 6 hours after treatment. However, optimal
blood sampling in similar studies of mice bearing human colon can-
cer xenografts treated with the aurora kinase inhibitor AZD1152 was
24 hours after drug administration [46]. The biomarker analyses sug-
gest that early M65 changes (within the first week of therapy) may
predict likelihood of radiologic response to combination treatment.
However, this only occurred when the statistical analysis focused on in-
dividual patient profiles. No significant differences were detected when
biomarkers were compared between infusion groups. As with other bio-
marker studies in phase 1 trials, their value is best seen with longitudinal
patient data because small heterogenous patient groups with inherent
Figure 3. Synergistic combination of obatoclax, cisplatin and etoposide in SCLC cells. (A) H526 cells were treated with obatoclax for
48 hours followed by the addition of cisplatin and etoposide for 48 hours. Equipotent concentrations of the single agents were selected
to cover the concentration-effect curve; the x axis shows the fixed ratio. Data are representative of six SCLC cell lines. (B) SCLC cells
were treated either concurrently with the three drugs for 96 hours or 48 hours with the first agent (termed cytotoxics) followed by the
addition of obatoclax for 48 hours, covering the concentration-effect curve. After 96 hours, surviving fraction was determined using the
MTS assay, and synergy was evaluated using CalcuSyn software.
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Figure 4. Pharmacodynamic biomarker analysis from the phase 1 trial of obatoclax in combination with cisplatin and etoposide in SCLC.
(A) Schematic for clinical trial drug administration for obatoclax, cisplatin, and etoposide and timing of blood samples for pharmaco-
dynamic biomarker analysis. Patients could receive up to six cycles of chemotherapy. (B) Circulating caspase cleaved plus full-length
CK18 levels (M65 assay) in “responders” (n = 17) and “nonresponders” (n = 7). Statistical analysis by Wilcoxon matched-pairs signed
rank test. (C) Percentage change from pretreatment baseline values in full-length plus caspase cleaved CK18 (M65 assay) and nucleo-
somal DNA (nDNA assay) between day 3 circulating biomarker increases and day 8 decreases (P = .002 and P = .02, respectively), and
group comparisons between patients who received the 3-hour infusion and those who received the 24-hour infusion.
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interpatient differences and baseline variability make group compari-
sons less sensitive. A phase 1 trial of obatoclax in combination with
topotecan has recently been published [22], demonstrating that the
combination was well tolerated with no apparent elevation in circulat-
ing caspase cleaved CK18 (M30). The lack of rise in M30 is pertinent
to chemotherapy tolerability because a rise in M30 has previously been
correlated with severe toxicity requiring hospitalization in patients with
SCLC receiving platinum-based chemotherapy [24]. Obatoclax was
also safely administered in combination with full doses of carboplatin
and etoposide, but because of practical issues with the 24-hour infu-
sion arm, the 3-hour 30-mg maximum tolerated dose was selected
for a randomized phase 2 versus carboplatin and etoposide alone; the
results of which are eagerly awaited.
These data extend our knowledge showing that obatoclax promotes
cell death synergistically in combination with platinum/etoposide in
SCLC and is optimized by drug scheduling. Applied clinically, this
raises the possibility of chemotherapy dose reduction with maintained
efficacy. The data presented here suggest that blood samples drawn
24 hours after completion of therapy for pharmacodynamic cell death
biomarker analysis are likely to be most informative in future trials in-
corporating obatoclax.
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